04Mar 2023
Type‐4 Phosphodiesterase (PDE4) Blockade Reduces Neutrophil activation in Behçet's disease

Type‐4 Phosphodiesterase (PDE4) Blockade Reduces Neutrophil activation in Behçet's disease

The study aimed to investigate the effect of PDE4 inhibition on neutrophil activation in Behçet's disease (BD), a systemic vasculitis. The study found that neutrophil activation surface markers, reactive oxygen species (ROS) production, and neutrophils extracellular traps (NETs) were upregulated in BD compared to healthy donors. Transcriptome analysis showed significant dysregulation of neutrophil genes related to innate immunity, intracellular signaling, and chemotaxis in BD. PDE4 inhibition by apremilast strongly inhibited neutrophil surface activation markers, ROS production, NETosis, and genes and pathways related to innate immunity, intracellular signaling, and chemotaxis. The study highlights the key biological effects of apremilast on neutrophils in BD.

  • #rheumatology

Like

Save

Share